nach oben

International Journal of Clinical Oncology

Erschienen in:

01.10.2015 | Original Article

Long-term results of definitive concurrent chemoradiotherapy for patients with esophageal submucosal cancer (T1bN0M0)

verfasst von: Yuji Murakami, Ippei Takahashi, Ikuno Nishibuchi, Yoshiko Doi, Tomoyuki Okabe, Masahiro Kenjo, Tomoki Kimura, Yasushi Nagata

Erschienen in: International Journal of Clinical Oncology | Ausgabe 5/2015

Einloggen, um Zugang zu erhalten

Abstract

Background

The long-term outcomes of definitive concurrent chemoradiotherapy for patients with esophageal submucosal cancer without regional and distant metastasis were retrospectively analyzed.

Methods

Patients with histologically confirmed esophageal submucosal cancers without regional and distant metastasis who received definitive concurrent chemoradiotherapy from 2001 to 2011 were included. Radiation therapy of a median total dose of 60 Gy/30 fractions (range, 54–66 Gy) with elective nodal irradiation of 40 Gy was combined concurrently with 5-furuorouracil-based chemotherapy.

Results

Thirty-six patients (33 men and 3 women) aged from 45 to 80 years (median, 67 years) were assessed. All patients had squamous cell carcinoma. With a median follow-up time of 61 months, the 5-year overall survival, disease-free survival, and locoregional failure-free survival rates were 86 % [95 % confidence interval (CI), 74–99 %], 59 % (95 % CI, 42–77 %), and 90 % (95 % CI, 79–100 %), respectively. Late toxicities of grade 3 pleural effusion in 2 patients, grade 4 pericardial effusion in 1 patient, and grade 5 pneumonitis in 1 patient were observed. Metachronous esophageal cancer was observed in 8 patients (22 %). Among them, 6 patients with mucosal legions were salvaged by endoscopic resection.

Conclusion

Our long-term results of concurrent chemoradiotherapy (CCRT) for patients with esophageal submucosal cancer showed acceptable toxicities and favorable locoregional control and survivals while maintaining organ preservation.

Hareyama M, Nishio M, Kagami Y et al (1992) Intracavitary brachytherapy combined with external-beam irradiation for squamous cell carcinoma of the thoracic esophagus. Int J Radiat Oncol Biol Phys 24:235–240CrossRefPubMed

Okawa T, Dokiya T, Nishio M et al (1999) Multi-institutional randomized trial of external radiotherapy with or without intraluminal brachytherapy for esophageal cancer in Japan. Int J Radiat Oncol Biol Phys 45:623–628CrossRefPubMed

Yorozu A, Dokiya T, Oki Y (1999) High-dose-rate brachytherapy boost following concurrent chemoradiotherapy for esophageal carcinoma. Int J Radiat Oncol Biol Phys 45:271–275CrossRefPubMed

Maingon P, Hombres A, Truc G et al (2000) High dose rate brachytherapy for superficial cancer of the esophagus. Int J Radiat Oncol Biol Phys 46:71–76CrossRefPubMed

Ishikawa H, Nonaka T, Sakurai H et al (2010) Usefulness of intraluminal brachytherapy combined with external beam radiation therapy for submucosal esophageal cancer: long-term follow-up results. Int J Radiat Oncol Biol Phys 76:452–459CrossRefPubMed

Yamada K, Murakami M, Okamoto Y et al (2006) Treatment results of chemoradiotherapy for clinical stage I (T1N0M0) esophageal cancer. Int J Radiat Oncol Biol Phys 64:1106–1111CrossRefPubMed

Kato H, Sato A, Fukuda H et al (2009) A phase II trial of chemoradiotherapy for stage I esophageal squamous cell carcinoma: Japan Clinical Oncology Group study (JCOG9708). Jpn J Clin Oncol 39:638–643CrossRefPubMed

Murakami Y, Nagata Y, Nishibuchi I et al (2012) Long-term outcomes of intraluminal brachytherapy in combination with external beam radiotherapy for superficial esophageal cancer. Int J Clin Oncol 17:263–271CrossRefPubMed

Ozawa S, Tachimori Y, Baba H et al (2012) Comprehensive Registry of Esophageal Cancer in Japan, 2004. Esophagus 9:75–98CrossRef

10.

Nishimaki T, Tanaka O, Suzuki T et al (1993) Tumor spread in superficial esophageal cancer: histopathologic basis for rational surgical treatment. World J Surg 17:766–772CrossRefPubMed

11.

Makuuchi H, Shimada H, Mizutani K et al (1997) Clinical pathological analysis of surgically resected superficial esophageal carcinoma to determine criteria for deciding on treatment strategy. Diagn Ther Endosc 3:211–220PubMedCentralCrossRefPubMed

12.

Tachibana M, Yoshimura H, Kinugasa S et al (1997) Clinicopathological features of superficial squamous cell carcinoma of the esophagus. Am J Surg 174:49–53CrossRefPubMed

13.

Kodama M, Kakegawa T (1998) Treatment of superficial cancer of the esophagus: a summary of responses to a questionnaire on superficial cancer of the esophagus in Japan. Surgery (St. Louis) 123:432–439CrossRef

14.

Endo M, Yoshino K, Kawano T et al (2000) Clinicopathologic analysis of lymph node metastasis in surgically resected superficial cancer of the thoracic esophagus. Dis Esophagus 13:125–129CrossRefPubMed

15.

Bollschweiler E, Baldus SE, Schröder W et al (2006) High rate of lymph-node metastasis in submucosal esophageal squamous-cell carcinomas and adenocarcinomas. Endoscopy 38:149–156CrossRefPubMed

16.

Takahashi H, Arimura Y, Hosokawa M et al (2010) Endoscopic submucosal dissection is superior to conventional endoscopic resection as a curative treatment for early squamous cell carcinoma of the esophagus (with video). Gastrointest Endosc 72:255–264CrossRefPubMed

17.

Altorki NK, Lee PC, Liss Y, Meherally D et al (2008) Multifocal neoplasia and nodal metastases in T1 esophageal carcinoma: implications for endoscopic treatment. Ann Surg 247:434–439CrossRefPubMed

18.

Tachibana T, Matono S, Nagano T et al (2012) Esophagectomy with extended lymphadenectomy for submucosal esophageal cancer: long-term outcomes and prognostic factors. Ann Surg Oncol 19:750–756CrossRef

19.

Nemoto K, Yamada S, Nishio M et al (2006) Results of radiation therapy for superficial esophageal cancer using the standard radiotherapy method recommended by the Japanese Society of Therapeutic Radiology and Oncology (JASTRO) Study Group. Anticancer Res 26:1507–1512PubMed

20.

Murakami Y, Kenjo M, Uno T et al (2007) Results of the 1999–2001 Japanese Patterns of Care Study for patients receiving definitive radiation therapy without surgery for esophageal cancer. Jpn J Clin Oncol 37:493–500CrossRefPubMed

21.

Herskovic A, Martz K, Al-Sarraf M et al (1992) Combined chemotherapy and radiotherapy compared with radiotherapy alone in patients with cancer of the esophagus. N Engl J Med 326:1593–1598CrossRefPubMed

22.

Al-Sarraf M, Martz K, Herskovic A et al (1997) Progress report of combined chemoradiotherapy versus radiotherapy alone in patients with esophageal cancer: an intergroup study. J Clin Oncol 15:277–284PubMed

23.

Cooper JS, Guo MD, Herskovic A et al (1999) Chemoradiotherapy of locally advanced esophageal cancer: long-term follow-up of a prospective randomized trial (RTOG 85-01) Radiation Therapy Oncology Group. JAMA 281:1623–1627CrossRefPubMed

24.

Gasper L, Winter K, Kocha W et al (2000) A phase I/II study of external beam radiation, brachytherapy, and concurrent chemotherapy for patients with localized carcinoma of the esophagus (Radiation Therapy Oncology Group Study 9207). Cancer (Phila) 88:988–995CrossRef

25.

Shimizu Y, Tukagoshi H, Fujita M et al (2001) Metachronous squamous cell carcinoma of the esophagus arising after endoscopic mucosal resection. Gastrointest Endosc 54:190–194CrossRefPubMed

26.

Urabe Y, Hiyama T, Tanaka S et al (2009) Metachronous multiple esophageal squamous cell carcinomas and Lugol-voiding lesions after endoscopic mucosal resection. Endoscopy 41:304–309CrossRefPubMed

27.

Adams MJ, Hardenbergh PH, Constine LS et al (2003) Radiation-associated cardiovascular disease. Crit Rev Oncol Hematol 45:55–75CrossRefPubMed

28.

Ishikura S, Nihei K, Ohtsu A et al (2003) Long-term toxicity after definitive chemoradiotherapy for squamous cell carcinoma of the thoracic esophagus. J Clin Oncol 21:2697–2702CrossRefPubMed

29.

Lin SH, Wang L, Myles B et al (2012) Propensity score-based comparison of long-term outcomes with 3-dimensional conformal radiotherapy vs. intensity-modulated radiotherapy for esophageal cancer. Int J Radiat Oncol Biol Phys 84:1078–1085PubMedCentralCrossRefPubMed

Titel: Long-term results of definitive concurrent chemoradiotherapy for patients with esophageal submucosal cancer (T1bN0M0)
verfasst von: Yuji Murakami
Ippei Takahashi
Ikuno Nishibuchi
Yoshiko Doi
Tomoyuki Okabe
Masahiro Kenjo
Tomoki Kimura
Yasushi Nagata
Publikationsdatum: 01.10.2015
Verlag: Springer Japan
Erschienen in: International Journal of Clinical Oncology / Ausgabe 5/2015
Print ISSN: 1341-9625
Elektronische ISSN: 1437-7772
DOI: https://doi.org/10.1007/s10147-015-0819-2

Neu im Fachgebiet Onkologie

Mehr Lebenszeit mit Abemaciclib bei fortgeschrittenem Brustkrebs?

24.05.2024 Mammakarzinom Nachrichten

In der MONARCHE-3-Studie lebten Frauen mit fortgeschrittenem Hormonrezeptor-positivem, HER2-negativem Brustkrebs länger, wenn sie zusätzlich zu einem nicht steroidalen Aromatasehemmer mit Abemaciclib behandelt wurden; allerdings verfehlte der numerische Zugewinn die statistische Signifikanz.

ADT zur Radiatio nach Prostatektomie: Wenn, dann wohl länger

24.05.2024 Prostatakarzinom Nachrichten

Welchen Nutzen es trägt, wenn die Strahlentherapie nach radikaler Prostatektomie um eine Androgendeprivation ergänzt wird, hat die RADICALS-HD-Studie untersucht. Nun liegen die Ergebnisse vor. Sie sprechen für länger dauernden Hormonentzug.

Das sind die führenden Symptome junger Darmkrebspatienten

23.05.2024 Leitsymptome in der Hausarztpraxis Nachrichten

Darmkrebserkrankungen in jüngeren Jahren sind ein zunehmendes Problem, das häufig längere Zeit übersehen wird, gerade weil die Patienten noch nicht alt sind. Welche Anzeichen Ärzte stutzig machen sollten, hat eine Metaanalyse herausgearbeitet.

„Überwältigende“ Evidenz für Tripeltherapie beim metastasierten Prostata-Ca.

22.05.2024 Prostatakarzinom Nachrichten

Patienten mit metastasiertem hormonsensitivem Prostatakarzinom sollten nicht mehr mit einer alleinigen Androgendeprivationstherapie (ADT) behandelt werden, mahnt ein US-Team nach Sichtung der aktuellen Datenlage. Mit einer Tripeltherapie haben die Betroffenen offenbar die besten Überlebenschancen.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Long-term results of definitive concurrent chemoradiotherapy for patients with esophageal submucosal cancer (T1bN0M0)